AIRCHILL Investor Snapshot
AIRCHILL · Investor Snapshot · Last reviewed 18 August 2026
What exists today. What the next round is designed to prove, measure and scale.
Development-stage · TRL ≈ 4 · no CE mark · no FDA clearance · not for patient use · no established clinical benefit
Medical Cooling / AIRCHILL public development status
AIRCHILL is being developed as a transport-ventilation platform with controlled respiratory cooling for time-critical care. This page is the short first-read layer before the full investor data room.
The three questions first-time investors need answered
1. What exists today?
A physical laboratory demonstrator and a defined product concept; granted European and US patent rights; published and project-level mechanism/safety evidence; a public evidence, regulatory and market-access diligence layer.
2. What will the next programme validate?
The programme is designed to generate the first AIRCHILL patient-performance and safety dataset, freeze a minimum certifiable configuration that is hardware-complete where mature purchased/OEM subsystems can be integrated proportionately, complete the QMS/verification package, define a focused first intended purpose and claim set, validate customer and reimbursement assumptions, and then prospectively test and size indication-specific clinical benefit. Most peripheral hardware is expected to be bought or integrated rather than invented in-house; the proprietary development effort is concentrated on respiratory cooling, the gas path, control and safe system integration. The aim is to avoid paying for a disposable hardware-limited MVP and then creating a second major integration and change-control programme before the commercially relevant configuration. The component-by-component standards, OEM-vs-own-development, cost and time matrix is published here.
3. What does the next round finance?
The €7.5m planning round is designed around roughly 30 months of engineering, QMS/regulatory work, verification and validation, preclinical preparation and the path toward a planned first-in-patient feasibility gate in 2029.
Current financing frame
- Current round: €7.5m planning case
- Planned runway: 30 months
- Indicative follow-on after Gate B: €10–15m
- First-in-patient feasibility: planned for 2029
- Base-case commercial revenue through 2031: €0
- Planning values are assumptions, not commitments, forecasts or guarantees
What the public evidence supports
The public record provides a concrete rationale for the next programme: AIRCHILL produced rapid local brain-temperature changes in the porcine model, project-level preclinical airway-safety work supports continued development, exploratory human measurements demonstrated local temperature change, and external animal timing/dose evidence shows that timing, depth and duration can materially influence neuroprotection. The next clinical studies are designed to reproduce product-level performance, establish patient safety and test and size patient benefit; those objectives are not yet presented as completed clinical outcomes.
The value-creation questions that should shape valuation and closing conditions
- Clinical validation target: prior airway-cooling trials define the phenotype, timing, thermal-separation and endpoint questions that AIRCHILL’s prospective programme is designed to test and size.
- Engineering validation target: the planned endotracheal product route will quantify whether redesigned flow, circuit geometry, inspiratory temperature and exposure can overcome the 2017 dead-space heat-transfer limitation while preserving ventilation and airway safety.
- EU Class IIb remains a planning assumption; US 510(k) versus De Novo remains to be tested through regulatory interaction.
- The granted patents are founder-controlled; assignment or an exclusive worldwide sublicensable licence to the operating company remains a defined financing step.
- Founder capacity, full-time leadership, QA/RA ownership and execution-team buildout require documentary de-risking.
- Customer discovery, signed LOIs, procurement validation and final pricing/unit economics are not represented as completed.
Next value-inflection gate
The immediate investment case is not based on assumed revenue. It is based on converting a TRL ≈ 4 development programme into a verified, controlled and regulator-ready product package with explicit stop/go criteria. The strongest next milestone is a completed bench, airway-safety and verification package that materially reduces product and regulatory uncertainty.
Diligence path
- Read the AIRCHILL product page for architecture, product scope and current status.
- Review the evidence page and research register for what is supported versus still hypothetical.
- Review regulatory and reimbursement assumptions separately from clinical claims.
- Use the Investor Data Room for the public document register, gaps and restricted-material map.
- Request transaction-sensitive documents only once investor fit is established.
AIRCHILL is a development-stage medical technology project. This page is for research, planning and investor-diligence orientation. It is not medical advice, a representation of regulatory approval, an offer of securities, an investment recommendation or a guarantee of future performance.